Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra (RBT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01259219 |
Recruitment Status
: Unknown
Verified December 2010 by Harriet Shezi Children's Clinic.
Recruitment status was: Recruiting
First Posted
: December 14, 2010
Last Update Posted
: December 14, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Children With Confirmed HIV Infection Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment | Drug: Mycobutin | Phase 1 |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra |
Study Start Date : | November 2010 |
Estimated Primary Completion Date : | June 2011 |
Estimated Study Completion Date : | June 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Rifabutin (Mycobutin)
Rifabutin is a red-violet powder souble in chloroform and methanol, sparingly souluble in ethanol, and very slightly soluble in water. Mycobutin capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. Mycobutin capsules for oral administered contain 150mg of rifabutin, USP, per capsule, along with the inactive ingredients microcrystalline cellulose magenesium stearate, red iron oxide3, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink.
|
Drug: Mycobutin
Indication and Usage: Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection. Dosage and Directions for use: Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens. Identification: Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder. |
- To assess dosing, pharmacokinetic profile, and safety of rifabutin when given concomitantly with LPV/RTV for 14 days in HIV-infected children age < 5 years. [ Time Frame: 6-12 months ]
- We hypothesize that a clinically significant drug interaction exists between rifabutin & /lopinavir/ritonavir in young children (age < 5 years) such that rifabutin dosing for concomitant administration of RBT & LPV/RTV needs to be developed [ Time Frame: 6-24 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
SELECTION AND ENROLLMENT OF SUBJECTS
Inclusion Criteria:
- Children with confirmed HIV infection. Confirmation can be by two rapid tests (children age > 18 months) or virologic test (children < 18 months), and detectable viral load prior to starting ARVs.
- Age ≤ 5 years old - rationale: changes in body composition and maturity of metabolizing enzymes and organs result in age-related differences in drug clearance, especially between children ≤ 5 years and children > 5 years of age.
- Receiving an ART regimen containing 2 NRTIs + LPV/RTV at standard dose
- Successfully completed TB treatment in the past 2 to 6 weeks. Successful completion of treatment will be defined as children with good clinical response (resolution of TB symptoms) to treatment.
Rationale:
- RBT has not yet been approved for treatment of TB in children. Participating children can therefore not be in need treatment for TB as this may lead to substandard treatment.
- RBT monotherapy in the presence of Mycobacterium tuberculosis can lead to the development of resistance. Excluding active TB is difficult in children, especially those that are HIV co-infected. Children who have just successfully completed a treatment for TB can be assumed to be free of Mycobacterium tuberculosis.
- A minimum of two weeks is needed between RIF and RBT administration to ensure wash-out of any enzyme inducing effects of RIF.
Exclusion Criteria
- History of symptomatic clinical hepatitis during TB treatment
- Abnormal liver function defined as ALT > 2.5 times the normal upper limit (corresponding to the US National Institute of Health Division of AIDS scale grade 2)
- Abnormal bilirubin defined as > 1.5 UNL (≥ DAIDS grade 2)
- Abnormal serum creatinine defined as >1.1 x ULN
- Anemia defined as hemoglobin < 8gm/dL
- Neutropenia defined as < 1.0 x 109/L(corresponding to grade 2)
- Abnormal platelets defined as <125 x 1012/L
- Pre-existing eye conditions
- Any condition that the clinician feels would predispose the child to toxicity
- Children required to take any drug known or predicted to interact with rifabutin (see appendix)
- Children who do not meet inclusion criteria and/or whose parents refuse consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01259219
Contact: Shobna Sawry, MSc (Med) Epi & Bio BScHonours | 27119339629 | shobnas@witsecho.org.za | |
Contact: Annelies Van Rie, MD & PhD | +1919 9661420 | vanrie@email.unc.edu |
South Africa | |
Harriet Shezi Children's Clinic, Chris Hani Baragwanath Hospital, WHI, University of the Witwatersrand | Recruiting |
Johannesburg, Gauteng, South Africa, 1864 | |
Contact: Hermien Gous, PharmD 27119388189 hermieng@witsecho.org.za | |
Harriet Shezi Children's Clinic, Chris Hani Baragwanath Hospital, WHI, University of the Witwatersrand | Recruiting |
Johannesburg, Gauteng, South Africa, 1864 | |
Principal Investigator: Henry (Harry) AJ Moultrie, MD | |
Harriet Shezi Children's Clinic | Recruiting |
Johannesburg, Gauteng, South Africa | |
Contact: Sonwabo Lindani, RN 27 11 933 9392 sonwabol@witsecho.org.za | |
Contact: Merleesa Govender 27 11 933 9630 merleesag@witsecho.org.za |
Principal Investigator: | Henry (Harry) JA Moultrie, MD, Master's in epi | Harriet Shezi Children's Clinic, Chris Hani Baragwanth Hospital, WHI, University of the Witwatersrand |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Dr Harry Moultrie, Harriet Shezi Children's Clinic, Chris Hani Baragwanath Hospital, WHI, University of the Witwatersrand |
ClinicalTrials.gov Identifier: | NCT01259219 History of Changes |
Other Study ID Numbers: |
Rifabutin (RBT) |
First Posted: | December 14, 2010 Key Record Dates |
Last Update Posted: | December 14, 2010 |
Last Verified: | December 2010 |
Keywords provided by Harriet Shezi Children's Clinic:
HIV Completion of TB treamtment |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immunologic Deficiency Syndromes Immune System Diseases Rifabutin Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antitubercular Antitubercular Agents |